HGR-ViT: Hand Gesture Recognition with Vision Transformer.

Hand gesture recognition (HGR) is a crucial area of research that enhances communication by overcoming language barriers and facilitating human-computer interaction. Although previous works in HGR have employed deep neural networks, they fail to encode the orientation and position of the hand in the image. To address this issue, this paper proposes HGR-ViT, a Vision Transformer (ViT) model with an attention mechanism for hand gesture recognition. Given a hand gesture image, it is first split into fixed size patches. Positional embedding is added to these embeddings to form learnable vectors that capture the positional information of the hand patches. The resulting sequence of vectors are then served as the input to a standard Transformer encoder to obtain the hand gesture representation. A multilayer perceptron head is added to the output of the encoder to classify the hand gesture to the correct class. The proposed HGR-ViT obtains an accuracy of 99.98%, 99.36% and 99.85% for the American Sign Language (ASL) dataset, ASL with Digits dataset, and National University of Singapore (NUS) hand gesture dataset, respectively.

Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus.

Dapagliflozin is an inhibitor of human renal sodium-glucose cotransporter 2 (SGLT2), first approved for the treatment of type 2 diabetes mellitus (T2DM). Dapagliflozin is primarily metabolized by uridine diphosphate glucuronosyltransferase 1A9 (UGT1A9). The effect of UGT1A9 polymorphisms on dapagliflozin apparent oral clearance (CL/F) was studied with dapagliflozin population pharmacokinetic data and UGT1A9 genotype data (I.399C>T, rs2011404, rs6759892, rs7577677, rs4148323, UGT1A9*2 and UGT1A9*3) from a Phase 2 study conducted in subjects with T2DM (n = 187). An analysis of covariance (ANCOVA) model accounting for known covariates influencing dapagliflozin CL/F was applied to these data to quantify the impact of each UGT1A9 polymorphism relative to the wildtype UGT1A9 genotype. The analysis showed that the geometric mean ratios of dapagliflozin CL/F for all of the UGT1A9 polymorphisms studied were within the range of wildtype UGT1A9 CL/F values. Consequently, the polymorphisms of UGT1A9 studied had no clinically meaningful impact on the CL/F of dapagliflozin.